The problem with generic scrips for m/r strong opioids
Authors
Abstract
The authors explain why modified‐release strong opioids should be prescribed by brand name, and how generic prescribing can actually lead to an increase in costs. Copyright © 2007 Wiley Interface Ltd
Digital Object Identifier (DOI)
10.1002/psb.145 About DOI
Login/Logout
Journal Menu
- Home
- News
- Current Issue
- Archive Issues
- Learning Central
- Ask Prescriber
- Prescriber Blog
- Forthcoming Events
- Supplements
- Wiley Job Network
Advertising and Sponsorship
Other Journals
